Novartis completes acquisition of Tourmaline Bio
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Strengthening capabilities in Peptide Therapeutics and CDMO services
Positions Curium as leading manufacturer of Lu-177 isotope
Subscribe To Our Newsletter & Stay Updated